A mathematical model of bone remodeling dynamics for normal bone cell populations and myeloma bone disease

Biology Direct

Volumn 5, Issue , 2010, Pages

  Ayati, Bruce P ^a   Edwards, Claire M ^b   Webb, Glenn F ^c   Wikswo, John P ^c  

^a UNIVERSITY OF IOWA   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; ARTICLE; BONE REMODELING; CYTOLOGY; HUMAN; MULTIPLE MYELOMA; OSTEOCLAST; OSTEOCYTE; PATHOLOGY; PHYSIOLOGY; THEORETICAL MODEL;

ANIMALS; BONE REMODELING; HUMANS; MODELS, THEORETICAL; MULTIPLE MYELOMA; OSTEOCLASTS; OSTEOCYTES;

EID: 77952956420     PISSN: None     EISSN: 17456150     Source Type: Journal    
DOI: 10.1186/1745-6150-5-28     Document Type: Article

References (38)

1. Parfit AM. Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem 1994, 55:273-86. 10.1002/jcb.240550303, 7962158.
2. Martin MJ, Buckland-Wright JC. Sensitivity analysis of a novel mathematical model identifies factors determining bone resorption rates. Bone 2004, 35:918-928. 10.1016/j.bone.2004.06.010, 15454099.
3. Lekszycki T. Functional Adaptation of Bone as an Optimal Control Problem. J Theoretical Applied Mechanics 2005, 43(3):555-574.
4. Maldonado S, Borchers S, Findeisen R, Allgöwer F. Mathematical Modeling and Analysis of Force Induced Bone Growth. Proceedings of the 28th IEEE EMBS Annual International Conference, New York 2006,
5. Martínez G, Aznar JMG, Doblaré M, Cerrolaza M. External bone remodeling through boundary elements and damage mechanics. Mathematics and Computers in Simulation 2006, 73:183-199.
6. Tezuka KI, Wada Y, Takahashi A, Kikuchi M. Computer-simulated bone architecture in a simple bone-remodeling model based on a reaction-diffusion system. J Bone Miner Metab 2005, 23:1-7. 10.1007/s00774-004-0533-z, 15616887.
7. Lemaire V, Tobin FL, Greller LD, Cho CR, Suva LJ. Modeling the interactions between osteoblast and osteoclast activities in bone remodeling. J Theor Biol 2004, 229:293-309. 10.1016/j.jtbi.2004.03.023, 15234198.
8. García-Aznar JM, Rueberg T, Doblare M. A bone remodelling model coupling microdamage growth and repair by 3D BMU-activity. Biomech Model Mechanobiol 2005, 4:147-167. 10.1007/s10237-005-0067-x, 15942795.
9. Moroz A, Wimpenny DI. Allosteric control model of bone remodelling containing periodical modes. Biophysical Chemistry 2007, 127:194-212. 10.1016/j.bpc.2007.02.001, 17321664.
10. Pivonka P, Zimak J, Smith DW, Gardiner BS, Dunstan CR, Sims NA, Martin TJ, Mundy GR. Model structure and control of bone remodeling: A theoretical study. Bone 2008, 43:249-263. 10.1016/j.bone.2008.03.025, 18514606.
11. Restrepo JM, Choksi R, Jiang JMHY. Improving the damage accumulation in a biomechanical bone remodelling model. Computer Methods in Biomechanics and Biomedical Engineering 2009, 12(3):341-352.
12. Ryser MD, Nigam N, Komarova SV. Mathematical Modeling of Spatio-Temporal Dynamics of a Single Bone Multicellular Unit. J Bone Mineral Research 2009, 24(5):860-870.
13. Mundy GR. Myeloma bone disease. European J Cancer 1998, 34:246-251.
14. Mundy GR, Raisz LG, Cooper RA, Schechter GP, Salmon S. Evidence for the secretion of an osteoclast stimulating factor in myeloma. New England J Medicine 1974, 291:1041-1046.
15. Bataille R, Chappard D, Marcelli C, Dessauw P, Baldet P, Sany J, Alexandret C. Recruitment of New Osteoblasts and Osteoclasts Is the Earliest Critical Event in the Pathogenesis of Human Multiple Myeloma. J Clin Invest 1991, 88:62-66. 10.1172/JCI115305, 296003, 2056131.
16. Valentin OA, Charhon SA, Meunier PJ, Edouard CM, Arlot ME. Quantitative histology of myeloma-induced bone changes. British J Haematology 1982, 52:601-610.
17. Taube T, Beneton MNC, McCloskey EV, Rogers S, Greaves M, Kanis JA. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. European J Haematology 1992, 49:192-198.
18. Evans CE, Galasko CS, Ward C. Does myeloma secrete an osteoblast inhibiting factor?. J Bone Joint Surg Br 1989, 71:288-290.
19. Bataille R, Delmas PD, Chappard D, Sany J. Abnormal serum bone Gla protein levels in multiple myeloma. Crucial role of bone formation and prognostic implications. Cancer 1990, 66:167-172. 10.1002/1097-0142(19900701)66:1<167::AID-CNCR2820660130>3.0.CO;2-9, 2354403.
20. Abildgaard N, Rungby J, Glerup H, Brixen K, Kassem M, Brincker H, Heickendorff L, Eriksen EF, Nielsen JL. Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma. Eur J Haematol 1998, 61:128-134.
21. Woitge HW, Horn E, Keck AV, Auler B, Seibel MJ, Pecherstorfer M. Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis. Clin Chem 2001, 47:686-693.
22. Komarova SV, Smith RJ, Dixon SJ, Sims SM, Wahl LM. Mathematical model predicts a critical role for osteoclast autocrine regulation in the control of bone remodeling. Bone 2003, 33:206-215. 10.1016/S8756-3282(03)00157-1, 14499354.
23. Akchurin T, Aissiou T, Kemeny N, Prosk E, Nigam N, Komarova SV. Complex Dynamics of Osteoclast Formation and Death in Long-Term Cultures. PLoS ONE 2008, 3(5):e2104. 10.1371/journal.pone.0002104, 2330067, 18461134.
24. Komarova SV. Mathematical Model of Paracrine Interactions between Osteoclasts and Osteoblasts Predicts Anabolic Action of Parathyroid Hormone on Bone. Endocrinology 2005, 146(8):3589-3595. 10.1210/en.2004-1642, 15860557.
25. Komarova SV. Bone Remodeling in Health and Disease: Lessons From Mathematical Modeling. Ann NY Acad Sci 2006, 1068:557-559. 10.1196/annals.1346.052, 16831951.
26. Edwards CM, Lwin ST, Fowler JA, Oyajobi BO, Zhuang J, Bates AL, Mundy GR. Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo. Am J Hematol 2009, 84(5):268-272. 10.1002/ajh.21374, 2753224, 19296472.
27. Garrett IR, Chen D, Gutierrez G, Zhao M, Escobedo A, Rossini G, Harris SE, Gallwitz W, Kim KB, Hu S, Crews CM, Mundy GR. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 2003, 111(11):1771-1782. 10.1172/JCI16198, 156102, 12782679.
28. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, Gupta D, Richardson PG, Munshi NC, Anderson KC. Proteasome Inhibitor PS-341 Inhibits Human Myeloma Cell Growth in Vivo and Prolongs Survival in a Murine Model. Cancer Research 2002, 62:4996-5000.
29. Oyajobi BO, Garrett IR, Gupta A, Flores A, Esparza J, Munoz S, Zhao M, Mundy GR. Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. British J Haematology 2007, 139(3):434-438.
30. Pennisi A, Li X, Ling W, Khan S, Zangari M, Yaccoby S. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol 2008, 84:6-14.
31. Uy GL, Trivedi R, Peles S, Fisher NM, Zhang QJ, Tomasson MH, Dipersio JF, Vij R. Bortezomib inhibits osteoclast activity in patients with multiple myeloma. Clin Lymphoma Myeloma 2007, 7:587-589. 10.3816/CLM.2007.n.045, 18186967.
32. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC. The Proteasome Inhibitor PS-341 Inhibits Growth, Induces Apoptosis, and Overcomes Drug Resistance in Human Multiple Myeloma Cells. Cancer Research 2001, 61:3071-3076.
33. Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A, Pouli A, Katodritou E, Verrou E, Vervessou EC, Dimopoulos, Meletios-Athanassios, Croucher PI. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-[kappa]B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. British J Haematology 2006, 135(5):688-692.
34. Zavrski I, Krebbel H, Wildemann B, Heider U, Kaiser M, Possinger K, Sezer O. Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. Biochem Biophys Res Commun 2005, 333:200-205. 10.1016/j.bbrc.2005.05.098, 15936724.
35. Bozec A, Bakiri L, Hoebertz A, Eferl R, Schilling A, Komnenovic V, Scheuch H, Priemel M, Stewart C, Amling M, Wagner E. Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia. Nature 2008, 454:221-225. 10.1038/nature07019, 18548006.
36. Kohn D, Sarmadi M, Helman J, Krebsbach P. Effects of pH on human bone marrow stromal cells in vitro: implications for tissue engineering of bone. J Biomed Mater Res 2002, 60:292-299. 10.1002/jbm.10050, 11857436.
37. Fortney J, Zhao W, Wenger S, Gibson L. Bone marrow stromal cells regulate caspase 3 activity in leukemic cells during chemotherapy. Leuk Res 2001, 25:901-907. 10.1016/S0145-2126(01)00051-0, 11532524.
38. Kirshner J, Thulien K, Martin L, Debes Marun C, Reiman T, Belch A, Pilarski L. A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. Blood 2008, 112:2935-2945. 10.1182/blood-2008-02-142430, 18535198.